FACT SHEET

MANULIFE DANA EKUITAS INDONESIA CHINA - IDR

FEB 2025

To generate capital appreciation by investing in medium to long term in Indonesian equities and/or companies listed on the Hong Kong stock exchange (including China Hshares and red chip companies) that derive majority of their revenue from China.

Fund Information


Inception Date 3 Mar 10 Inception Price IDR 1.000.00 Rp 141.71 bn Fund Size 84,000,740.28 Number of unit IDR 1,687.00 Net Asset Value/Unit 4 IDR Fund Currency Type of fund Equity Valuation Daily

Custodian Bank Standard Chartered Bank

Annual Management Fee 2.50% Bloomberg Code MLLDECI IJ

Fund Manager PT Manulife Aset Manaiemen Indonesia

Risk Classification



Note

- Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
- 2) The benchmark is 85% JCI + 15% Hang Seng Mainland 25 Index in IDR terms
- 3) Based on GICS (Global Industrials Classification Standard)
- 4) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Performance Since Inception

Monthly Performance Last 3 Years



Performance in IDR per (28/02/25)												
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ¹⁾	5 yr ¹⁾	Since Inception 1)				
MDEIC (in IDR)	-7.58%	-7.53%	-9.98%	-8.38%	-7.64%	-12.38%	2.85%	3.55%				
BM 2)	-7.75%	-6.48%	-10.67%	-7.25%	-5.08%	-0.71%	3.32%	5.87%				

Yearly Performance											
	2024	2023	2022	2021	2020	2019	2018	2017			
MDEIC (in IDR)	-3.32%	-15.01%	-10.34%	39.62%	4.12%	-0.80%	-7.69%	16.32%			
BM ²⁾	3.25%	3.32%	2.74%	6.21%	-4.43%	2.97%	-3.58%	22.14%			

Top Holdings* & Sector Allocation3

Stock - Alibaba Group Holding Ltd Stock - Aneka Tambang Tbk Stock - Astra International Tbk PT Stock - Bank Aladin Syariah Tbk PT Stock - Bank Central Asia Tbk PT Stock - Bank Mandiri Persero Thk PT Stock - Bank Negara Indonesia Persero Tbk PT

Stock - Bank of China Ltd

Stock - Bank Pan Indonesia Tbk PT

Stock - Bank Rakyat Indonesia Persero Tbk PT

Stock - Bank Syariah Indonesia Tbk PT

Stock - Bundamedik Tbk PT Stock - BYD Co Ltd

Stock - Chandra Asri Pacific Tbk PT

Stock - GoTo Gojek Tokopedia Tbk PT

Stock - Hillcon Tbk PT


Stock - Impack Pratama Industri Tbk PT

Stock - Indofood CBP Sukses Makmur Tbk PT Stock - Indofood Sukses Makmur Tbk PT

*Non Affiliates

Stock - Indosat Tbk PT Stock - Mayora Indah Tbk PT Stock - Panin Financial Tbk PT Stock - Telkom Indonesia Persero Tbk PT Stock - Tencent Holdings Ltd

Stock - Triputra Agro Persada PT Stock - United Tractors Tbk PT Stock - Xiaomi Corp Stock - XL Axiata Tbk PT



Investment Manager Commentary

Equity market posted negative performance in February due to uncertainty on US tariff policy and concern on weak domestic growth. President Trump affirms that 25% against imports from Canada and Mexico will proceed in early March, along with 10% additional tariff against China. President Trump also indicate that further tariffs would follow in April, to impose reciprocal tariffs against countries that imposed tariffs on US. Domestically, concerns on weak domestic growth and uncertainty on government policy transition weighed on market sentiment. There was deflation -0.09% YOY in February, seen by the market as indication of weak domestic consumption. Meanwhile the government announced further budget efficiency to reach IDR750 trillion to be reallocated to priorities program such as Free Nutritious Lunch program, and forming Danantara. Bank Indonesia maintained BI Rate at 5.75% amid weak Rupiah that depreciated -1.7% against USD to 16.580. However BI maintains outlook of further rate cut to support domestic growth. On the flip side, China equities rose in the month, driven by optimism on domestic tech sector following the release DeepSeek AI model. Portfolio allocations in utilities contributed positive attributions, meanwhile allocations in financials contributed negative attributions to performance.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequence. arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.









